| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/20/2011 | DE102009033396A1 Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung Aqueous solution and gelatinized composition comprising a phosphodiesterase-5 inhibitor, and related procedures and use |
| 01/20/2011 | DE102009033392A1 Heterocyclische Verbindungen als Autotaxin-Inhibitoren II Heterocyclic compounds as inhibitors Autotaxin II |
| 01/20/2011 | DE102009033208A1 Aminopyridinderivate Aminopyridine |
| 01/20/2011 | CA2768370A1 Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide |
| 01/20/2011 | CA2768299A1 Bifunctional stapled polypeptides and uses thereof |
| 01/20/2011 | CA2768291A1 3-hydroxypyrrolidine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase |
| 01/20/2011 | CA2768210A1 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt |
| 01/20/2011 | CA2768169A1 Aminopyridine derivatives for the treatment of tumors and inflammatory diseases |
| 01/20/2011 | CA2768095A1 Heterocyclic compounds as autotaxin inhibitors ii |
| 01/20/2011 | CA2767992A1 2 - [[[2 -[(hydroxyacetyl) amino]- 4 -pyridinyl] methyl] thio]- n -[4 - (trifluoromethoxy) phenyl]- 3 -pyridinecarboxamide benzenesulfonate, crystal of same, crystal polymorph thereof, and methods for production thereof |
| 01/20/2011 | CA2767091A1 Pyrrolopyrazine inhibitors of kinases |
| 01/20/2011 | CA2767089A1 Pyrrolopyridine inhibitors of kinases |
| 01/19/2011 | EP2275575A2 Coding sequence haplotypes of the human BRCA2 gene |
| 01/19/2011 | EP2275574A2 Coding sequence haplotypes of the human BRCA2 gene |
| 01/19/2011 | EP2275557A1 Albumin fusion proteins |
| 01/19/2011 | EP2275548A1 Mammalian cytokine receptor subunit proteins, related reagents and methods |
| 01/19/2011 | EP2275537A1 Anti-human dlk-1 antibody having anti-tumor activity in vivo |
| 01/19/2011 | EP2275450A1 Treatment with anti-ERBB2 antibodies |
| 01/19/2011 | EP2275449A1 Antibodies that immunospecifically bind to blys |
| 01/19/2011 | EP2275447A1 Methods of inhibiting metastasis |
| 01/19/2011 | EP2275446A2 Antibodies to insulin-like growth factor I receptor |
| 01/19/2011 | EP2275445A2 Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth |
| 01/19/2011 | EP2275444A1 Chimeric anti CD44 antibodies and their use for treating acute myeloid leukemia |
| 01/19/2011 | EP2275437A1 Polypeptide and pharmaceutical composition containing the polypeptide |
| 01/19/2011 | EP2275433A1 Metastin derivative and use thereof |
| 01/19/2011 | EP2275425A1 Novel crystalline forms of temozolomide |
| 01/19/2011 | EP2275416A1 Biologically active methylene blue derivatives |
| 01/19/2011 | EP2275411A2 Reformatsky Reagent in Stable Form and Process for Producing the Same |
| 01/19/2011 | EP2275143A2 Conjugated anti-psychotic drugs and uses thereof |
| 01/19/2011 | EP2275142A2 Conjugates for immunotherapy of cancer |
| 01/19/2011 | EP2275140A2 Composition comprising plant and/or fish oils and non-oxidizable fatty acid entities |
| 01/19/2011 | EP2275137A1 Metallic nanoparticles, preparation and uses thereof |
| 01/19/2011 | EP2275136A1 Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody |
| 01/19/2011 | EP2275135A1 Therapeutic for hepatic cancer |
| 01/19/2011 | EP2275134A2 Use of ADCC-optimized antibodies for treating weak patients |
| 01/19/2011 | EP2275115A2 Inhibition of stress-induced ligand-dependent EGFR activation |
| 01/19/2011 | EP2275114A1 Pharmaceutical composition for treating or preventing cancer which induces dendritic cell-like differentiation of monocytes to increase anticancer immune activity |
| 01/19/2011 | EP2275112A1 Antitumoral terpenoid pharmaceutical composition 'abisilin' exhibiting angiogenesis-inhibiting action |
| 01/19/2011 | EP2275107A2 Combinations for the treatment of diseases involving cell proliferation |
| 01/19/2011 | EP2275103A2 mTOR inhibitors in the treatment of endocrine tumors |
| 01/19/2011 | EP2275102A1 N3 alkylated benzimidazole derivatives as MEK inhibitors |
| 01/19/2011 | EP2275091A1 Pharmaceutical compositions comprising adsorbates of an amorphous drug |
| 01/19/2011 | EP2274309A1 Halichondrin b analogs |
| 01/19/2011 | EP2274308A1 Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors |
| 01/19/2011 | EP2274304A1 Method of treating cancer using a cmet and axl inhibitor and an erbb inhibitor |
| 01/19/2011 | EP2274303A1 Processes for preparing sunitinib and salts thereof |
| 01/19/2011 | EP2274301A1 Aza-bicyclohexyl substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
| 01/19/2011 | EP2274294A1 5-demethoxyfumagillol and derivatives thereof |
| 01/19/2011 | EP2274285A1 Novel pyrazole derivatives |
| 01/19/2011 | EP2274283A1 Novel n-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds |
| 01/19/2011 | EP2274282A1 Compounds for use in stabilizing p53 mutants |
| 01/19/2011 | EP2274053A2 Use of the human pancreatic polypeptide as a therapeutic agent |
| 01/19/2011 | EP2274018A1 Modified hydroxypolymer conjugates with bone seeking and tumor killing moieties |
| 01/19/2011 | EP2274017A2 Vascular delivery systems |
| 01/19/2011 | EP2274012A1 Cytotoxic immunoglobulin |
| 01/19/2011 | EP2274008A2 Compositions and methods for inhibiting pdgfrbeta and vegf-a |
| 01/19/2011 | EP2274006A2 Angiostatic compositions comprising truncated tyrosyl-trna synthetase polypeptides and methods of using same |
| 01/19/2011 | EP2274005A2 Treatment of tumors |
| 01/19/2011 | EP2274001A2 Heat shock protein gp96 vaccination and methods of using same |
| 01/19/2011 | EP2273882A1 Bioactive compounds for treatment of cancer and neurodegenerative diseases |
| 01/19/2011 | EP2150546B1 Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase |
| 01/19/2011 | EP2150527B1 Anthranilic acid derivative as anticancer agent and a process for the preparation thereof |
| 01/19/2011 | EP2068938B1 Optimization of the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitor imatinib |
| 01/19/2011 | EP1693456B1 Method of identifying modulators of a g protein-coupled receptor |
| 01/19/2011 | EP1668036B1 Method for the production of human antibodies blocking the biological activity of a human cytokine |
| 01/19/2011 | EP1608623B1 Metal ion chelators and therapeutic use thereof |
| 01/19/2011 | EP1481969B1 Piperidine derivative compounds and drugs containing the compounds as the active ingredient |
| 01/19/2011 | EP1432416B1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 01/19/2011 | EP1411962B1 Monoclonal antibody therapy for pancreas cancer |
| 01/19/2011 | EP1409008B1 Use of a nucleic acid molecule coding the disintegrin domain of an adamalysin as anti-angiogenic, anti-invasive and anti-metastatic agent |
| 01/19/2011 | EP1365808B1 Compositions for antitumour treatment containing ecteinascidin 743 |
| 01/19/2011 | EP1337234B1 Use of 2-oxothiazolidine 4-carboxylic acid derivatives as agents promoting skin peeling |
| 01/19/2011 | EP1330442B1 Phthalazinone derivatives |
| 01/19/2011 | EP1325019B1 Antisense modulation of clusterin expression |
| 01/19/2011 | EP1252300B1 Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| 01/19/2011 | EP1185296B1 Prevention and treatment of amyloidogenic diseases |
| 01/19/2011 | CN1816543B Indole derivatives with apoptosis-inducing effect |
| 01/19/2011 | CN1814302B Method for selectively increasing tumor cell sensitivity to ionic radiation |
| 01/19/2011 | CN101952433A PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease |
| 01/19/2011 | CN101952429A STAT3 epitope peptides |
| 01/19/2011 | CN101952426A Anti-BST2 antibody |
| 01/19/2011 | CN101952320A Material with immunogenicity |
| 01/19/2011 | CN101952319A Anti-mesothelin antibodies and uses therefor |
| 01/19/2011 | CN101952315A Agents targeting CD138 and uses thereof |
| 01/19/2011 | CN101952302A New polypeptides having affinity for HER2 |
| 01/19/2011 | CN101952297A Solid forms of ortataxel |
| 01/19/2011 | CN101952291A 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5h-pyrimido [4, 5-B[1, 4] diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases PLK41 to PLK4 for the treatment of proliferative diseases |
| 01/19/2011 | CN101952286A Bicyclic derivatives for use in the treatment of androgen receptor associated conditions |
| 01/19/2011 | CN101952282A Thiazole derivatives used as PI 3 kinase inhibitors |
| 01/19/2011 | CN101952255A Compounds for inhibiting KSP kinesin activity |
| 01/19/2011 | CN101951960A Conjugates of anti-RG-1 antibodies |
| 01/19/2011 | CN101951959A Anti-B7H4 monoclonal antibody-drug conjugate and methods of use |
| 01/19/2011 | CN101951956A Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
| 01/19/2011 | CN101951954A Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6) |
| 01/19/2011 | CN101951953A Pharmaceutical composition comprising anti-GRP78 antibody as active ingredient |
| 01/19/2011 | CN101951932A Extract of piper betel leaves for the treatment of human malignancies by inducing oxidative stress |
| 01/19/2011 | CN101951930A Oral or enteral composition useful for recovery of physical functions |
| 01/19/2011 | CN101951910A Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib |
| 01/19/2011 | CN101951907A Antitumoral agents with a benzophenanthridine structure and formulations containing them |
| 01/19/2011 | CN101951905A Use of aminopeptidase inhibitors or azaindole compounds for preventing or treating cancerous metastases from epithelial origin |